| 1 |
31102151 | Genotyping and phenotyping CYP3A4\CYP3A5: no association with antiplatelet effect of clopidogrel. | 2019 Aug |
1 |
| 2 |
29777510 | Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention. | 2018 Oct |
1 |
| 3 |
30422888 | Investigating the Effect of Demographics, Clinical Characteristics, and Polymorphism of MDR-1, CYP1A2, CYP3A4, and CYP3A5 on Clopidogrel Resistance. | 2018 Dec |
1 |
| 4 |
26426352 | The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes. | 2016 Feb |
5 |
| 5 |
26961113 | Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke. | 2016 Oct 1 |
3 |
| 6 |
27649539 | Association between CYP3A5 polymorphisms and the risk of adverse events in patients undergoing clopidogrel therapy: Meta-analysis. | 2016 Nov |
2 |
| 7 |
25730082 | Diversity of platelet function and genetic polymorphism in clopidogrel-treated Chinese patients. | 2015 Feb 13 |
1 |
| 8 |
26099919 | The impact of genetic polymorphisms of drug metabolizing enzymes on the pharmacodynamics of clopidogrel under steady state conditions. | 2015 Aug |
2 |
| 9 |
24763934 | Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease. | 2014 Jun |
1 |
| 10 |
25112801 | Single nucleotide polymorphism of CYP3A5*3 contributes to clopidogrel resistance in coronary artery disease patients among Tamilian population. | 2014 Nov |
5 |
| 11 |
23333143 | Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. | 2013 Feb 26 |
1 |
| 12 |
22265638 | The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients. | 2012 Apr 1 |
1 |
| 13 |
22735685 | Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. | 2012 Sep |
2 |
| 14 |
21153923 | The investigation of allele and genotype frequencies of CYP3A5 (1/3) and P2Y12 (T744C) in Iran. | 2011 Nov |
1 |
| 15 |
19067731 | The genetics of antiplatelet drug resistance. | 2009 Jan |
1 |
| 16 |
19337788 | Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome. | 2009 Mar |
2 |
| 17 |
18385991 | Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. | 2008 Jun |
3 |
| 18 |
17361128 | Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. | 2007 May |
1 |
| 19 |
16754899 | Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. | 2006 Jun 6 |
4 |